MEETINGS - On Strategies in the Non/minimally Invasive Diagnostic Market (UK) December 1999:
This article was originally published in Clinica
A meeting on Strategies in the Non/Minimally Invasive Diagnostic Market will take place in London on December 6-7. It will cover European and global regulatory issues, strategic partnering, cost effectiveness of centralised laboratory testing, differing approaches to cancer diagnostics and risk stratification and diagnostic tools. Two workshops will also take place on Dec 8 - Strategic Planning for a Successful In Vitro Diagnostics Portfolio and Regulatory and Reimbursement Strategies in the Diagnostics Industry. Further details may be obtained from SMi in the UK. Tel: +44 20 7252 2222. Fax: +44 20 7252 2272.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.